Brief: Jiangsu Recbio Technology Says Increased Capacity For First Phase Of HPV Vaccine Manufacturing
21/11/2022 10:20
Nov 21 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* CAPACITY FOR FIRST PHASE OF CO'S HPV VACCINE MANUFACTURING
FACILITY TO BE INCREASED TO ANNUAL OUTPUT OF 20 MILLION DOSES
Source text for Eikon: ID:
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares